Mark H. Mirochnick, MD

Professor, Pediatrics

Mark Mirochnick


Mark Mirochnick, MD is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. His main research activities involve investigating the pharmacology of HIV and TB drugs in newborns, infants, children and pregnant women. He has served as protocol chair, investigator and/or protocol pharmacologist on many international protocol teams in this area. He currently serves as co-chair of the US Perinatal HIV Guidelines Committee and is a member of the US Pediatric HIV Guidelines Committee and the WHO Pediatric Antiretroviral Working Group.

Other Positions

  • Section Director, Neonatology, Pediatrics, Boston University School of Medicine


  • University of Vermont College of Medicine, MD
  • Dickinson College, BSc


  • Published on 7/6/2020

    Bustinduy AL, Kolamunnage-Dona R, Mirochnick MH, Capparelli EV, Tallo V, Acosta LP, Olveda RM, Friedman JF, Hope WW. Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women infected with Schistosoma japonicum. Antimicrob Agents Chemother. 2020 Jul 06. PMID: 32631820.

    Read at: PubMed
  • Published on 5/25/2020

    Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, Mirochnick M, Best BM, van den Anker JN, Dallmann A. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2020 May 25. PMID: 32451908.

    Read at: PubMed
  • Published on 5/1/2020

    João EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouvèa MIS, de Lourdes B Teixeira M, Fuller TL, Mmbaga BT, Ngocho JS, Njau BN, Violari A, Mathiba R, Essack Z, Pilotto JHS, Moreira LF, Rolon MJ, Cahn P, Prommas S, Cressey TR, Chokephaibulkit K, Werarak P, Laimon L, Hennessy R, Frenkel LM, Anthony P, Best BM, Siberry GK, Mirochnick M. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020 May; 7(5):e322-e331. PMID: 32386720.

    Read at: PubMed
  • Published on 5/1/2020

    Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020 May 01; 84(1):70-77. PMID: 31913995.

    Read at: PubMed
  • Published on 4/1/2020

    Eke AC, Stek AM, Wang J, Kreitchmann R, Shapiro DE, Smith E, Chakhtoura N, Capparelli EV, Mirochnick M, Best BM. Darunavir Pharmacokinetics With an Increased Dose During Pregnancy. J Acquir Immune Defic Syndr. 2020 Apr 01; 83(4):373-380. PMID: 31923087.

    Read at: PubMed
  • Published on 3/24/2020

    Eke AC, Wang J, Amin K, Shapiro DE, Stek A, Smith E, Chakhtoura N, Basar M, George K, Knapp KM, João EC, Rungruengthanakit K, Capparelli E, Burchett S, Mirochnick M, Best BM. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrob Agents Chemother. 2020 03 24; 64(4). PMID: 32015036.

    Read at: PubMed
  • Published on 3/17/2020

    Eke AC, Brooks KM, Gebreyohannes RD, Sheffield JS, Dooley KE, Mirochnick M. Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opin Drug Metab Toxicol. 2020 Apr; 16(4):333-342. PMID: 32125906.

    Read at: PubMed
  • Published on 2/1/2020

    Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, Siberry GK, Fenton T, Cababasay M, Fowler MG. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):173-180. PMID: 31929405.

    Read at: PubMed
  • Published on 12/1/2019

    Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):392-398. PMID: 31658182.

    Read at: PubMed
  • Published on 9/13/2019

    Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D. Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019 09 13; 69(7):1254-1258. PMID: 30783649.

    Read at: PubMed

View 116 more publications: View full profile at BUMC

View all profiles